checkAd

    EQS-Adhoc  133  0 Kommentare Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

    Für Sie zusammengefasst
    • Executive Board member Jens Ravens leaves Epigenomics AG on April 30, 2024.
    • Ravens' departure is due to the successful transfer of assets to New Day Diagnostics LLC.
    • The Supervisory Board will appoint a new Executive Board member in due course.

    EQS-Ad-hoc: Epigenomics AG / Key word(s): Personnel
    Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

    30-Oct-2023 / 15:49 CET/CEST
    Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.


    Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024

    Berlin, Germany, October 30, 2023 – Jens Ravens, Executive Board member of Epigenomics AG (Frankfurt General Standard: ECX1, the “Company”), leaves the Executive Board of the Company with effect as of April 30, 2024, due to the successful transfer of nearly all assets of the Company to New Day Diagnostics LLC. The Supervisory Board will appoint a new Executive Board member in due course and decide on the further composition of the Executive Board.

     

    Contact:
    Company
    Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
    Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com

    Investor Relations
    IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com


    Note on forward-looking statements

    This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

     



    End of Inside Information

    30-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.eqs-news.com


    Language: English
    Company: Epigenomics AG
    Bertha-Benz-Straße 5
    10557 Berlin
    Germany
    Phone: +49 30 24345-0
    Fax: +49 30 24345-555
    E-mail: ir@epigenomics.com
    Internet: www.epigenomics.com
    ISIN: DE000A32VN83
    WKN: A32VN8
    Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
    EQS News ID: 1760753

     
    End of Announcement EQS News Service

    1760753  30-Oct-2023 CET/CEST

    fncls.ssp?fn=show_t_gif&application_id=1760753&application_name=news&site_id=wallstreet

    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-Adhoc Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 EQS-Ad-hoc: Epigenomics AG / Key word(s): Personnel Epigenomics AG: Executive Board member Jens Ravens leaves the Company on April 30, 2024 30-Oct-2023 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation …